SciMed Solutions

07/28/2026

What's the biggest downfall for startups?

According to Dr. Bruce Bloom, it often comes down to a lack of focus:

"There are lots of opportunities, and everything looks really interesting. The kind of people who come to work for a startup are naturally very curious and want to take on a lot of work. Because of that, you can easily get yourself overly distributed, and then you lose your way."

Curiosity is a superpower when you are building a company from scratch, but without a strict filter, it can also become a small team's silent killer.

In our latest episode, Bruce joins us to break down the operational grit required to scale small teams without losing sight of the primary goal. Having led both for-profit biotechs and rare disease nonprofits, he shares his playbook for surviving the "scaling trap" and explains how to successfully navigate a bootstrapped pipeline.

We also dive deep into the fascinating molecular biology behind his latest venture, Fortuity Pharma, and how they are using translational readthrough to target genetic nonsense mutations.

Listen to the full episode, The Generalist Guide to Biotech Startups and Genetic Readthrough, on our website.

🎧 https://www.scimed.io/new/bruce-bloom

07/21/2026

When a small biotech startup begins to find success, the temptation to expand rapidly and chase every interesting opportunity is incredibly high. But as Dr. Bruce Bloom shared on our latest podcast episode, losing focus is one of the quickest ways for an early-stage company to disappear.

Bruce has led teams across both for-profit biotechs and rare disease nonprofits, and he utilizes a brilliant operational framework he calls being "broad but not deep." In a team of fewer than 25 people, early leaders must step in to organize unfamiliar departments—whether it is legal, business development, or clinical operations—with the explicit goal of hitting the next milestone and then immediately handing the keys over to a deep-domain specialist.

We also discussed the structural "elasticity" that allows nonprofits to survive market downturns far better than rigid for-profits, alongside a fascinating look into how Fortuity Pharma is using translational readthrough to bypass genetic nonsense mutations and prevent blindness in children.

The full episode is out now - check it out to hear a masterclass in bootstrapped operational grit and rare disease innovation

🎧 https://www.scimed.io/news/bruce-bloom

06/02/2026

“I was fed up with that [pipetting]... I think it is inefficient and waste of time, as humans we shouldn't do those repetitive boring tasks. To me microfluidics was the key to solve this problem.”

If you’ve spent any time around labs, you know it’s true. A lot of incredibly smart people are still tied up doing repetitive work — not because it adds value, but because that’s how the system has always been set up.

In our latest episode of the SciMed Biotech Podcast, Saren Tasciyan - the Founder of BioPeak - gets into how that’s starting to shift. We talk about microfluidics, better data workflows, and what it looks like to move toward labs that are actually designed for scale.

The interesting part isn’t just the tech — it’s what it unlocks. Less time on manual processes, more time on thinking, analyzing, and pushing things forward.

🎧 Listen to the full episode: https://www.scimed.io/news/saren-tasciyan-biopeak

05/26/2026

Most biology labs still run on manual workflows — pipetting, repetitive assays, and fragmented data systems. But that’s starting to change.

In our latest episode of the SciMed Biotech Podcast, we sit down with Saren Tasciyan, Founder of BioPeak, to explore how biology is moving from hands-on experimentation to automated, software-driven systems.

We get into:
🐌 Why so much scientific work is still inefficient — and where the biggest bottlenecks are
🪣How microfluidics is enabling a shift from “bucket-based” lab work to fully integrated systems
📅What it looks like to design scalable, flexible data workflows from day one

The big idea: scientists shouldn’t be spending their time on repetitive tasks — they should be focused on insight, analysis, and discovery.

If you’re thinking about how to scale research, improve throughput, or modernize lab infrastructure, this one is worth a listen.

🎧 Listen here: https://www.scimed.io/news/saren-tasciyan-biopeak

Visit SciMed for innovative medical technology solutions. Discover our services, ongoing projects, and how we can support your needs efficiently.

05/19/2026

“We’re not just trying to kill cancer cells—we’re trying to turn off the signal that’s driving them.”

That’s how Scott Thacher, CEO of Orphagen Pharmaceuticals, Inc., reframes the fight against cancer in our latest episode of the SciMed Biotech Podcast.

Instead of targeting cancer downstream, Orphagen is focused on the molecular “on switches” that control gene expression—specifically nuclear receptors like SF1. The goal: develop precise, small-molecule therapies that interrupt the disease at its source.

This approach is being applied to adrenocortical cancer, a rare and aggressive disease with limited treatment options—where innovation isn’t just valuable, it’s urgently needed.

The episode explores how emerging science, smart clinical strategy, and real-world constraints like funding all intersect in the journey to bring a first-in-class therapy to patients.

🎧 Listen here: https://www.scimed.io/news/scott-thacher-orphagen

05/12/2026

What if cancer isn’t just something to “kill”… but something you can turn off?

In our latest episode of the SciMed Biotech Podcast, we sit down with Scott Thacher, CEO of Orphagen Pharmaceuticals, Inc., to explore a novel approach to treating cancer at its source—by targeting the molecular “on switches” that control gene expression.

The conversation centers on adrenocortical cancer, a rare and aggressive disease with limited treatment options and a poor prognosis. Orphagen’s approach focuses on nuclear receptors like SF1, aiming to develop small-molecule therapies that precisely regulate the biological pathways driving tumor growth.

This episode explores:

🎯 How insights from the human genome are unlocking entirely new therapeutic targets
🚀Why rare diseases present both scientific opportunity and unique regulatory advantages
💊 The role of precision medicine in improving outcomes while minimizing off-target effects

It’s a comprehensive look at how innovative science is translated into potential therapies—and what it takes to bring them to patients who need them most.

🎧 Listen here: https://www.scimed.io/news/scott-thacher-orphagen

Visit SciMed for innovative medical technology solutions. Discover our services, ongoing projects, and how we can support your needs efficiently.

04/09/2026

"One of the very common approaches in drug discovery is something called docking..." - Chuck Reynolds, Founder of Gfree Bio

In the latest episode of the SciMed Biotech Podcast, Dr. Charles Reynolds explains how docking simulations allow scientists to test how potential drug molecules might bind to their targets before they’re ever synthesized in the lab.

By modeling these interactions computationally, researchers can better understand molecular behavior and design more effective drug candidates.

Listen to the full episode here: https://www.scimed.io/news/chuck-reynolds-gfree-bio

hashtag hashtag hashtag

04/02/2026

Drug discovery is often imagined as a purely experimental process happening in the lab.

But today, many of the most important decisions happen inside a computer first.

In the latest episode of the SciMed Biotech Podcast, we sat down with Dr. Chuck Reynolds, founder of Gfree Bio, to discuss how computational chemistry is helping scientists design better drugs before they ever synthesize them.

We discuss how molecular modeling and docking simulations help scientists predict how drugs interact with proteins, guide medicinal chemistry decisions, and accelerate the iterative process of drug discovery. Chuck also shares how advances in computing power and machine learning are expanding what’s possible in computational drug design.

If you’re interested in the intersection of biotech, computational modeling, and drug discovery, this episode provides a great overview of how these tools are shaping modern pharma R&D.

Listen to the episode here: https://www.scimed.io/news/chuck-reynolds-gfree-bio

03/26/2026

AI in healthcare gets a lot of attention for big ideas about replacing doctors. In reality some of the most useful applications are much simpler.

During our conversation on the SciMed Biotech Podcast, Paul Nanda shared how his team has been using AI powered documentation through Microsoft DAX Copilot within their Epic system.

The tool listens during the visit and generates the clinical note automatically.

It may only save two or three minutes per patient chart. But when a physician sees fifty patients in a day that can add up to nearly two hours saved.

What stood out in the conversation was that the value is not just efficiency. It is time. Less time typing. More time listening to patients. More time explaining care.

Listen to the conversation on our website 🎧
https://scimed.io/news/paul-nanda-tgh-urgent-care-official

03/19/2026

Urgent care didn’t grow simply because it was convenient. It grew because patients needed another option when they could not quickly access primary care.

On the SciMed Biotech Podcast we spoke with Paul Nanda, Chief Medical Officer of TGH Urgent Care powered by Fast Track, about how urgent care emerged to fill that gap and how technology is now pushing the model even further.

Remote diagnostic tools that cost only a few hundred dollars can now help physicians examine a patient’s eyes, ears, throat, heart, lungs, and vital signs from a distance. What once required expensive telemedicine kiosks is becoming something patients can use right from home.

It is a reminder that urgent care is no longer only a place you go. It is gradually becoming a more distributed way to deliver care while still maintaining quality clinical exams.

Listen in on our website 🎧
https://scimed.io/news/paul-nanda-tgh-urgent-care-official

Dr. Paul Nanda has delivered babies in Zimbabwe, supported displaced Ukrainian refugees in Warsaw, and now leads urgent care initiatives across the Tampa Bay region. In this episode, he shares how his global medical missions—from Haiti to New Zealand—have shaped his perspective on healthcare acc...